Disclosure of interest: All authors : nothing to disclose Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P1000 - ESOC25-739 WATCHMAN: 5-YEAR REAL-WORLD LONG-TERM OUTCOMES IN AF PATIENTS WITH LEFT APPENDAGE CLOSURE Jiangyong Min 1 , Beenish Javaid 1 , Richard Nguyen 2 , Asad Ahrar 1 , Nadeem Khan 1 , Malgorzata Miller 1 , Nabil Wees 1 , Elizabeth Evans 1 , Maulik Kantawala 1 , Tarah Moelker 1 , Musa Dahu 1 , William Merhi 1 , Duane Berkompas 1 1 Corewell Health West, Michigan State University, Grand Rapids, United States, 2 Michigan State University College of Human Medicine, Michigan State University, Grand Rapids, United States Background and Aims: Left appendage occlusion (LAAO) with Watchman has been proven to be an effective alternative to warfarin
That's the key to it
many vendors ship explicitly under research-use-only terms with the consignee declaring laboratory or institutional use
BPC-157 and TB-500 are experimental research peptides that have garnered attention in the context of regenerative medicine and tissue repair due to their promising preclinical results
